A 66-year old man with severe functional mitral regurgitation ( Figure 1A ) secondary to chronic ischemic cardiomyopathy (previous myocardial infarction and coronary artery bypass grafting) and advanced heart failure (left ventricular ejection fraction: 25%; New York Heart Association [NYHA] functional class III) was considered to be at very high surgical risk and was finally accepted by the Heart Team for transcatheter mitral valve implantation (TMVI) with the FORTIS transcatheter valve (Edwards Lifesciences, Irvine, California) ( Figures 1B and 1C) .
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The procedure was performed using previously described techniques (1). In brief, the valve was inserted in the left ventricular cavity using a 40- 
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APPENDIX For accompanying videos, please see the online version of this article. showing a turbulent jet generated in the septal wall (red arrow) (Online Video 4). (G) Cardiac magnetic resonance in the end-systolic phase. No significant mitral regurgitation was found using both a direct quantification method (mitral regurgitant volume: 2 ml; mitral regurgitant fraction: 4%) and indirect quantification method (mitral regurgitant volume: 2 ml; mitral regurgitant fraction: 2%; left ventricular stroke volume: 89 ml; left ventricular ejection fraction: 28%; aortic antegrade volume: 87 ml; aortic regurgitant volume: 1 ml). We observed an optimal position of the prosthesis in the mitral annulus. The "pseudo leak" seems to be generated in the virtual space (white star) between the native leaflets captured by the paddles (arrows) and the atrial part of the prosthesis (Online Video 5). 
